Shenzhen Efung Investment Management (Efung Capital) is a Shenzhen based life science venture capital firm. They focus investments in clinical-stage pharmaceutical and medical device companies already generating revenues. They look for investment in China and the United States.
Efung Capital has made investments in WeMed, Elicio Therapeutics, TriArm Therapeutics, Zhongyianke Biotech, Tactiva Therapeutics, KBP Biosciences, Centrexion Therapeutics, Ascentage Pharma, Chipscreen Biosciences, Frontier Biotech, Lifotronic, Healthgen Biotech, Aridis Pharmaceuticals, and Resverlogix.
Medical Strategy Officer
Chairman and President
Xiaoxiao Peng, PhD